Europe

Regulators at the HMA-EMA AI group on 5 October 2026 outlined AI guidance in clinical development, with a concept paper and public consultation to follow.

Social prescribing is not yet part of Portugal's national health system. Economists are asking whether it works, and who pays for it.

Health security in Europe is being redefined from emergency response to national resilience, and the EFPIA View argues it starts with funded health systems.

OHE's A Dose of Economics explores why medicines made for one patient challenge regulation, payment and HTA.

At the World Health Summit in Berlin, speakers from the European Commission, Japan, Africa, the Asian Development Bank and industry argued that health is a strategic economic asset, and asked how to persuade finance ministries. #SyenzaNews #HealthEconomics

AI is entering every stage of medical training. A new npj Digital Medicine Perspective maps how to integrate it responsibly across UGME, GME and CME.

Health utilities for multiple sclerosis fall with disability, and progressive forms score lowest. A UK cohort of 5,772 patients gives modellers EQ-5D and cost inputs by MS type and EDSS band. #SyenzaNews #MarketAccess

The EU's ACT EU advice pilot for clinical trial applications becomes permanent in January 2027, with updated sponsor guidance.

Uptake of new cancer medicines in Europe still varies, with a three-fold gap between countries in 2023.

Halozyme has won a Keytruda SC injunction in the Netherlands, ordering MSD to stop supplying the subcutaneous form of pembrolizumab in eight European markets. The case turned on how the patent's stability test is measured, and the injunction lapses country by country if a national court invalidates its part of EP 2 797 622. #SyenzaNews #oncology #patentlitigation #MarketAccess

A national study projects the liver cancer burden in Portugal will reach 4,851 cases and about 6,600 deaths by 2027, at a cost near 370 million euros. #SyenzaNews #oncology #hepatology

A new European Observatory toolkit says biosimilar uptake policies only work as a mix. Denmark pushed adalimumab biosimilars past 90%, Ireland shared €10 million of savings with clinical teams, and Finland cut reimbursement spending by €42 million. #SyenzaNews #Biosimilars #MarketAccess #HealthPolicy